Unilever heads into the back half of August with short sellers largely absent from the story — the real tension this week lies between a stock trading well below its analyst consensus target and momentum that has yet to turn in its favour.
The borrowing market tells a story of near-total indifference from short sellers. Short interest is negligible, and borrow availability is effectively uncapped — over 920 million shares remain available to lend, with cost to borrow running at just 0.56%, a level that reflects no meaningful demand from the bearish side. That figure has actually eased roughly 11% on the week, even after creeping up about 8% over the past month. The ORTEX short score of 26 — ranking in the 92nd percentile for low short-side pressure — reinforces the picture. Shorts are not a factor here in any direction.
Where the week's most interesting tension sits is the gap between price and Street expectations. The stock closed at £45.78 on Tuesday, down just over 0.6% on the week and roughly 2% over the past month. The mean analyst price target is £61.43 — implying around 34% upside from current levels. That is a wide gap, and it has widened as the stock drifted lower through the summer. No recent analyst changes appear in the data, so the consensus has effectively drifted further from the price by inertia rather than by active revision. The PE multiple has compressed to just under 16x — down nearly half a point over 30 days — while EV/EBITDA has eased to 11.7x, both moving in the direction that value-oriented investors would find more interesting. The price-to-book at 6.9x remains elevated for a consumer staples name, reflecting the brand portfolio premium the market historically assigns to Unilever. The dividend score ranks in the 68th percentile, a reminder that income investors still have reason to hold even as the price drifts.
The most notable institutional signal comes from Amundi, which added over 13 million shares in the period to July 30, and Sanders Capital, which built a position of nearly 14.2 million additional shares — both among the larger recent moves in a holder base that runs to 389 institutions. BlackRock, the largest holder at 8.5% of shares, added just under 9 million shares in the same period. These are not aggressive accumulations relative to the overall float, but they point to continued institutional appetite at current levels rather than distribution. On the insider side, activity is modest and low-significance: a small sell from a divisional president in late July, offset by director purchases earlier in the year. No meaningful insider signal either way.
The July 28 earnings print is worth noting for context. The stock moved nearly 8% higher on the day, the strongest single-day reaction in the recent history shown here. The five-day follow-through was more muted at 2.6%, suggesting the initial enthusiasm faded. That reaction came after a first-half result that the company's own recent note characterised as mixed — revenue growth of 2.3% with volume headwinds offset by margin work. The next event is scheduled for October 23, which gives the market roughly nine weeks to reassess before the next data point arrives.
With shorts sidelined, borrow conditions loose, and the next earnings still two months out, the question for ULVR watchers is whether the 34% gap between price and consensus begins to close through price recovery or through target downgrades — and whether the momentum deterioration flagged in recent score analysis finds a floor before October's print.
See the live data behind this article on ORTEX.
Open ULVR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
